Vanguard Capital Management
TSHA icon

Vanguard Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Vanguard Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85M Buy
12,478,595
+2,247,093
+22% +$13.3M ﹤0.01% 1641
2026
Q1 		$45.7M Buy
+10,231,502
New +$47.6M ﹤0.01% 1898

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management's TSHA Position: Q2 2026 in Review

Vanguard Capital Management increased its Taysha Gene Therapies (TSHA) stake by 22% in Q2 2026, buying an estimated $13.3M and bringing the position to 12,478,595 shares worth $85M. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Vanguard Capital Management first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Vanguard Capital Management held 12,478,595 shares of Taysha Gene Therapies worth $85M as of Q2 2026.
  • Vanguard Capital Management bought 2,247,093 Taysha Gene Therapies shares in Q2 2026, an estimated $13.3M.
  • Taysha Gene Therapies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1641 holding.
  • Vanguard Capital Management first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.